8-K/AOther Events

BIOGEN INC. 8-K/A Report (Oct 3, 2003)

Filed October 3, 2003For Securities:BIIB

Summary

This Form 8-K/A filing by IDEC Pharmaceuticals Corporation (the registrant, though the filing date references June 19, 2003, and the company name listed is IDEC Pharmaceuticals Corporation, the prompt asks for BIOGEN INC. (BIIB) analysis. This filing relates to an amended and restated collaboration agreement between IDEC Pharmaceuticals Corporation and Genentech, Inc. The agreement, dated June 19, 2003, concerns the development of new humanized anti-CD20 antibodies targeting B-cell disorders and coordinates commercial efforts for Rituxan. Key terms include shared development expenses for new products, joint marketing and sales efforts in the U.S., IDEC receiving royalty payments on products sold outside the U.S. and Canada, and shared operating profits/losses within the U.S. The agreement also outlines potential changes of control clauses, where Genentech might have the right to purchase IDEC's copromotion rights under certain conditions. This filing is an amendment to a previous 8-K, specifically to re-file a redacted version of the Collaboration Agreement.

Key Highlights

  • 1IDEC Pharmaceuticals and Genentech entered into an amended and restated collaboration agreement dated June 19, 2003.
  • 2The agreement focuses on developing new humanized anti-CD20 antibodies for B-cell disorders and coordinating commercial efforts for Rituxan.
  • 3Parties will share development expenses for new products and contribute specified personnel.
  • 4IDEC will receive royalty payments on products sold outside the U.S. and Canada; royalty period is 11 years from first commercial sale.
  • 5Both parties will share operating profits and losses on sales of products within the United States.
  • 6The agreement includes provisions for Genentech to potentially purchase IDEC's U.S. copromotion rights upon a change of control of IDEC.
  • 7This filing is an 8-K/A, primarily to re-file a redacted version of the Collaboration Agreement.

Frequently Asked Questions

The primary purpose of this 8-K/A filing is to re-file a redacted version of the Amended and Restated Collaboration Agreement between IDEC Pharmaceuticals Corporation and Genentech, Inc., dated June 19, 2003. It does not reflect events occurring after the original filing date.

For Rituxan sales within the United States, IDEC and Genentech will share operating profits and losses. IDEC recorded $192 million as its share of copromotion profits in the first half of 2003, and $324 million for the full year 2002. Outside the U.S. and Canada, IDEC will receive royalty payments for 11 years from the first commercial sale of each product.

The agreement includes a provision where, upon specified change of control events for IDEC, Genentech may present an offer to purchase IDEC's U.S. copromotion rights. IDEC would then have to either accept Genentech's offer or purchase Genentech's copromotion rights at a price determined by the offer and the parties' profit-sharing ratio.

The collaboration extends to the development of one or more new humanized anti-CD20 antibodies targeting B-cell disorders for a broad range of indications. Both parties will collaborate diligently, share development expenses for new products, and contribute specified personnel.